99 related articles for article (PubMed ID: 27527401)
1. Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient.
Vasudevamurthy AK; Ledet E; Garvey C; Lewis BE; Sartor O
Clin Genitourin Cancer; 2017 Feb; 15(1):e111-e113. PubMed ID: 27527401
[No Abstract] [Full Text] [Related]
2. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G; Antonarakis ES
Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
[No Abstract] [Full Text] [Related]
3. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T; Mizuno K; Yamasaki T; Miyazaki Y; Makino Y; Okasho K; Li X; Utsunomiya N; Goto T; Kobayashi T; Terada N; Inoue T; Kamba T; Fujimoto A; Ogawa O; Akamatsu S
Sci Rep; 2019 Mar; 9(1):4030. PubMed ID: 30858508
[TBL] [Abstract][Full Text] [Related]
5. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Antonarakis ES
Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
[No Abstract] [Full Text] [Related]
6. [The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():353-9. PubMed ID: 23513865
[No Abstract] [Full Text] [Related]
7. Targeting the androgen receptor in prostate cancer--a resilient foe.
Nelson PS
N Engl J Med; 2014 Sep; 371(11):1067-9. PubMed ID: 25184629
[No Abstract] [Full Text] [Related]
8. Words of wisdom: re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Luo J; Pienta KJ
Eur Urol; 2013 Aug; 64(2):339-40. PubMed ID: 23830228
[No Abstract] [Full Text] [Related]
9. Words of wisdom. Re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Schrader AJ; Schrader MG; Cronauer MV
Eur Urol; 2013 Jul; 64(1):169-70. PubMed ID: 23746320
[No Abstract] [Full Text] [Related]
10. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
Rezaei S; Mahjoubin Tehran M; Sahebkar A; Jalili A; Aghaee-Bakhtiari SH
J Cell Physiol; 2020 Apr; 235(4):3222-3234. PubMed ID: 31599460
[TBL] [Abstract][Full Text] [Related]
12. [Splicing variant of androgen receptors (AR-V7): New paradigms].
Penel N
Bull Cancer; 2016 Sep; 103(9):711-3. PubMed ID: 27591905
[No Abstract] [Full Text] [Related]
13. Resistance to androgen-pathway drugs in prostate cancer.
Steinestel J; Schrader AJ; Luedeke M
N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470703
[No Abstract] [Full Text] [Related]
14. Resistance to androgen-pathway drugs in prostate cancer.
Ozaki Y; Miura Y; Takano T
N Engl J Med; 2014 Dec; 371(23):2233-4. PubMed ID: 25470702
[No Abstract] [Full Text] [Related]
15. Resistance to androgen-pathway drugs in prostate cancer.
Şendur MA; Akıncı MB; Yalçın B
N Engl J Med; 2014 Dec; 371(23):2233. PubMed ID: 25470701
[No Abstract] [Full Text] [Related]
16. Resistance to androgen-pathway drugs in prostate cancer.
Antonarakis ES; Nakazawa M; Luo J
N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470700
[No Abstract] [Full Text] [Related]
17. AR-V7 predicts prostate cancer treatment response.
Cancer Discov; 2014 Nov; 4(11):OF1. PubMed ID: 25367950
[No Abstract] [Full Text] [Related]
18. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
19. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.
Shen HC; Balk SP
Cancer Cell; 2009 Jun; 15(6):461-3. PubMed ID: 19477425
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer: Wnt signalling induces resistance.
Sidaway P
Nat Rev Urol; 2015 Nov; 12(11):597. PubMed ID: 26439505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
